Economic Burden of Fungal Diseases in the United States

We conservatively estimated the US economic burden of fungal diseases as $11.5 billion in 2019: direct medical costs ($7.5 billion), productivity loss due to absenteeism ($870 million), and premature deaths ($3.2 billion). An alternative value of statistical life approach yielded >$48 billion. These are likely underestimates given underdiagnosis and underreporting. We conservatively estimated the U.S. economic burden of fungal diseases as $11.5 billion in 2019: direct medical costs ($7.5 billion), productivity loss due to absenteeism ($870 million), and premature deaths ($3.2 billion). These are likely underestimates given underdiagnosis and underreporting.

Automated summary

Conservatively estimated, the U.S. economic burden of fungal diseases in 2019 was $11.5 billion, including direct medical costs, productivity loss, and premature deaths. An alternative approach showed a value of over $48 billion. These estimates are likely low due to underdiagnosis and underreporting.